Cancer Evaluation Articles & Analysis
12 news found
Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that it is participating in the recently announced public-private Oncode-PACT. ...
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 development plans in head and neck ...
Oppenheimer's 32nd Annual Healthcare Conference Date: Tuesday, March 15, 2021 Time: 8:00 AM ET Presentation Format: Fireside Chat About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. Our DNA medicines are delivered using ...
About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to potentially treat and protect people from infectious diseases, cancer, and diseases associated with HPV. Our DNA medicines are delivered using our proprietary smart device to produce a robust and tolerable immune response against targeted pathogens and ...
The OHSU Knight Cancer Institute is at the forefront of multi-cancer early detection, including serving as a founding member of the MCED consortium, a group of leading cancer-focused organizations evaluating technologies that have the potential to reduce cancer mortality through earlier detection and providing ...
In addition, GI Innovation discussed the global KOL(Key opinion leader) including main cancer hospital researchers of the U.S. such as Washington University in St. ...
The clinical trial results demonstrate the ease of use and performance of SENSEI in prostate cancer surgery and signal potential application in other surgical procedures across major cancer types. ...
Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared to previous therapy 40% of patients experienced exceptional responses lasting at ...
The current study assessed the cost effectiveness of IsoPSA for the detection of high-grade, clinically actionable disease that may lead to downstream treatment of a primary cancer. Model inputs included established determinants of IsoPSA diagnostic accuracy (i.e., AUC, sensitivity, specificity, and predictive value), IsoPSA cost, and conservative estimates of costs associated ...
ROS1 gene fusions are prevalent in 1-2 percent of NSCLC cases. It is one of 46 cancer-related biomarkers evaluated by the MHLW-approved version of Thermo Fisher's Oncomine Dx Target Test. ...
Dr. Elizabeth Revesz has a unique background as an artist and sculptor. She was able to translate her precision, and her ability to see things in three dimensions, into a highly successful career in medicine. But once in the medical field, Dr. Revesz went further to find her true calling. “Medicine is great, but surgery is actually where I feel the most comfortable,” the physician ...
Although gastric cancer is more common in other parts of the world, in the U.S. 28,000 cases of stomach cancer will be diagnosed per year (17,750 in men and 10,250 in women), according to the American Cancer Society. About 10,960 people will die per year from this type of cancer (6,720 men and 4,240 women). Additionally, two new ...